Detection probe for mycoplasma genitalium and applications therefor
A labeled nucleic acid probe targeting the ParC gene of Mycoplasma genitalium allows for rapid and sensitive detection of both wild-type and antibiotic-resistant strains, addressing the limitations of current detection methods by simplifying the process and reducing detection time.
Patent Information
- Application Number
- JP2023070761
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-04-24
- Publication Date
- 2024-11-06
AI Technical Summary
Current methods for detecting Mycoplasma genitalium, particularly antibiotic-resistant strains, are not sensitive enough and require complex nucleic acid purification steps, leading to prolonged detection times.
A labeled nucleic acid probe with a specific base sequence targeting the ParC gene of Mycoplasma genitalium is used, allowing for rapid and sensitive detection of both wild-type and quinolone antibiotic-resistant mutants through nucleic acid amplification and melting curve analysis, eliminating the need for nucleic acid purification.
The method enables quick and highly sensitive detection of Mycoplasma genitalium, including antibiotic-resistant variants, reducing detection time to under 2 hours and facilitating accurate clinical diagnosis and appropriate treatment.
Smart Images

Figure 2024156361000005 
Figure 2024156361000006 
Figure 2024156361000007
Abstract
Description
[Technical field]
[0001] The present invention relates to a probe for detecting Mycoplasma genitalium, a method for detecting Mycoplasma genitalium using the probe, and a reagent / kit for use in the method. [Background technology]
[0002] Sexually transmitted diseases are diseases transmitted by sexual contact, and there are many cases where the infection is asymptomatic or mild and unnoticed, leading to the problem that the infection spreads without people realizing it. Representative examples of bacteria that cause sexually transmitted diseases include Chlamydia trachomatis and Neisseria gonorrhoeae. Other known causative bacteria include Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum, Ureaplasma urealyticum, Trichomonas vaginalis, and Treponema pallidum.
[0003] Among the bacteria that cause these sexually transmitted diseases, Mycoplasma genitalium has been reported to cause urethritis accompanied by purulent or serous urethral discharge, and it is important for clinical diagnosis to detect it simply, quickly, and with high sensitivity. Macrolide antibiotics are most commonly used to treat Mycoplasma genitalium infections. However, strains resistant to macrolide antibiotics have been reported, and cases in which treatment with macrolide antibiotics is difficult have been confirmed. Furthermore, quinolone antibiotics are also used to treat Mycoplasma genitalium infections, but strains resistant to quinolone antibiotics have also been reported (Non-Patent Document 1). [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Anna Vesty et al., Mycoplasma genitalium Antimicrobial Resistance in Community and Sexual Health Clinic Patients, Auckland, New Zealand., Journal of Emerging Infectious Diseases,February 2022 Volume 26 Number 2 Summary of the Invention [Problem to be solved by the invention]
[0005] There is a need to develop a method that can detect Mycoplasma genitalium as comprehensively as possible, regardless of whether it is wild-type or mutant. In addition, there is a need to develop a method that can not only detect both wild-type and mutant types, but also detect the presence or absence of antibiotic (e.g., quinolone antibacterial) resistance in Mycoplasma genitalium easily, quickly, and with high sensitivity. A main object of the present invention is to provide a probe useful for detecting Mycoplasma genitalium and a method for detecting Mycoplasma genitalium using the same. [Means for solving the problem]
[0006] As a result of intensive research to achieve the above object, the present inventors have found that Mycoplasma genitalium can be detected easily, quickly, and with high sensitivity by using a labeled probe having a specific base sequence. Based on this finding, the present inventors have further intensively researched and completed the present invention.
[0007] The present invention includes the following aspects. [Item 1] A probe for detecting Mycoplasma genitalium, having the following characteristics (A) and (B): (A) containing the following nucleotide sequence (A-1) or (A-2); (A-1) A base sequence of at least 15 consecutive bases in the base sequence of the region from base 72 to base 100 of the base sequence shown in SEQ ID NO: 1 or a base sequence complementary to the base sequence, the base sequence including at least a region of three bases corresponding to positions 247, 248, and 249 of the ParC gene sequence of Mycoplasma genitalium; or (A-2) a base sequence in which 1 to 3 bases are substituted, deleted, inserted or added in the base sequence of (A-1); and (B) Only either the 5' or 3' end is labeled. [Item 2] The probe described in Item 1, wherein in (A), the three bases at positions corresponding to 247, 248, and 249 of the ParC gene sequence in the base sequence shown in SEQ ID NO: 1 are each independently selected from an adenine base, a guanine base, and a thymine base. [Item 3] The probe described in Item 1 or 2, wherein in (A), the sequence consisting of three bases at positions corresponding to 247th, 248th, and 249th of the ParC gene sequence in the base sequence shown in SEQ ID NO: 1 is AGT or ATT. [Item 4] The probe according to any one of Items 1 to 3, wherein the base sequence of (A) comprises a base sequence shown in any one of SEQ ID NOs: 7 to 17 or a base sequence complementary thereto. [Item 5] The probe according to any one of Items 1 to 4, wherein the length of the base sequence of (A) is 15 to 30 bases. [Item 6] The probe according to any one of Items 1 to 5, wherein the label (B) is a fluorescent dye label. [Item 7] The probe according to any one of Items 1 to 6, wherein the label (B) is a label with a fluorescent quenching dye that is quenched when bound to a nucleic acid containing a base sequence that is 90% or more identical to a base sequence complementary to the base sequence of the probe. [Item 8] The probe according to any one of Items 1 to 7, wherein the label (B) is a label with a fluorescence quenching dye that is quenched by interaction with guanine. [Item 9] The probe according to any one of Items 1 to 8, wherein the label (B) is a label with at least one fluorescence quenching dye selected from the group consisting of fluorescein and derivatives thereof, rhodamine and derivatives thereof, and BODIPY and derivatives thereof. [Item 10] The probe according to any one of Items 1 to 9, wherein the label (B) is a label with at least one fluorescence quenching dye selected from the group consisting of 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid (BODIPY-FL), carboxyrhodamine 6G, TAMRA, rhodamine 6G, tetrabromosulfone fluorescein (TBSF), and 2-oxo-6,8-difluoro-7-dihydroxy-2H-1-benzopyran-3-carboxylic acid (Pacific Blue). [Item 11] The probe according to any one of Items 1 to 10, wherein in (B), the labeled terminal base is cytosine. [Item 12] A method for detecting Mycoplasma genitalium that may be contained in a specimen sample, using the probe according to any one of Items 1 to 11. [Item 13] The following steps (1), (2), and (3): (1) providing a specimen sample that may contain Mycoplasma genitalium; (2) subjecting the specimen sample of step (1) to a nucleic acid amplification reaction using a part or all of the ParC gene sequence of Mycoplasma genitalium as a template; and (3) detecting one or more nucleic acid amplification products that may be generated in the nucleic acid amplification reaction of step (2) using one or more of the probes; Item 13. The method according to item 12, comprising: [Item 14] The method according to Item 13, wherein step (2) is carried out by a PCR reaction, and the nucleic acid amplification enzyme used in the PCR reaction is a DNA polymerase belonging to Family B. [Item 15] The method according to Item 14, wherein the DNA polymerase belonging to Family B is a DNA polymerase derived from KOD or a mutant thereof. [Item 16] The method according to any one of Items 13 to 15, wherein the primer set used in the nucleic acid amplification reaction in step (2) is a primer set consisting of a combination of a first primer consisting of a base sequence of 19 to 32 consecutive bases in the base sequence of positions 1 to 71 of SEQ ID NO: 1 or a base sequence complementary to the base sequence, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said base sequence, and a second primer consisting of a base sequence of 19 to 32 consecutive bases in the base sequence of positions 99 to 142 of SEQ ID NO: 1 or a base sequence complementary to the base sequence, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said base sequence, wherein the second primer is a primer set complementary to a DNA extension product of the first primer. [Item 17] The method according to Item 16, wherein the first primer consists of a nucleotide sequence shown in any one of SEQ ID NOs: 18 and 19, or a complementary nucleotide sequence thereto, or a nucleotide sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said nucleotide sequence, and the second primer consists of a nucleotide sequence shown in any one of SEQ ID NOs: 20 to 22, or a complementary nucleotide sequence thereto, or a nucleotide sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said nucleotide sequence. [Item 18] A method according to any one of Items 12 to 17, which detects both wild-type and quinolone antibiotic-resistant mutant forms of Mycoplasma genitalium. [Item 19] The method according to any one of Items 12 to 18, which detects Mycoplasma genitalium by distinguishing whether it is a wild type or a mutant type resistant to a quinolone antibiotic. [Item 20] A method according to any one of Items 12 to 19, which discriminates and detects the presence or absence of at least one mutation at positions 247, 248, and 249 of the ParC gene sequence of Mycoplasma genitalium. [Item 21] A method according to any one of Items 12 to 20, which discriminates and detects the presence or absence of a mutation at position 248 of the ParC gene sequence of Mycoplasma genitalium. [Item 22] The method according to any one of Items 13 to 21, wherein the detection step in step (3) is carried out by melting curve analysis. [Item 23] The method according to Item 22, wherein in the melting curve analysis, a detection temperature of a quinolone antibiotic-resistant mutant is detected at a temperature lower or higher than the detection temperature of a wild-type mutant. [Item 24] The method according to Item 22 or 23, wherein in the melting curve analysis, the difference between the detection temperature of a quinolone antibiotic-resistant mutant and the detection temperature of a wild-type mutant is 4°C or more. [Item 25] The method according to any one of Items 22 to 24, wherein in the melting curve analysis, the difference between the detection temperature of a quinolone antibiotic-resistant mutant and the detection temperature of a wild type is 8°C or more. [Item 26] A reagent kit for detecting Mycoplasma genitalium, comprising the probe described in any one of Items 1 to 11. [Item 27] The reagent kit according to Item 26, further comprising a primer set consisting of a combination of a first primer consisting of a base sequence of 1 to 71 of the base sequence shown in SEQ ID NO: 1 or a base sequence of 19 to 32 consecutive bases in a base sequence complementary to the base sequence, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said base sequence, and a second primer consisting of a base sequence of 99 to 142 of the base sequence shown in SEQ ID NO: 1 or a base sequence of 19 to 32 consecutive bases in a base sequence complementary to the base sequence, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said base sequence, wherein the second primer is complementary to a DNA extension product of the first primer. Effect of the Invention
[0008] According to the present invention, Mycoplasma genitalium can be detected easily, quickly, and with high sensitivity. In addition, according to the present invention, it is possible to detect both wild-type and mutant Mycoplasma genitalium resistant to quinolone antibiotics by using one kind of probe. Furthermore, according to the present invention, it is possible to detect Mycoplasma genitalium by distinguishing whether it is wild-type or mutant resistant to quinolone antibiotics, and further, in a specific embodiment, it is possible to detect by distinguishing the presence or absence of a mutation at at least one of positions 247, 248, and 249 of the ParC gene sequence of Mycoplasma genitalium. By using the probe of the present invention, the detection method, reagent, or kit using the probe, Mycoplasma genitalium can be detected easily, quickly, and with high sensitivity, which can greatly contribute to the field of clinical diagnosis. [Brief description of the drawings]
[0009] [Figure 1] FIG. 1 shows a representative example of the results of Example 1 (detection results when melting curve analysis was carried out using the probe shown in SEQ ID NO:8). [Diagram 2] FIG. 2 shows a representative example of the results of Example 2 (detection results when melting curve analysis was carried out using the combination of primers shown in SEQ ID NO: 19 and SEQ ID NO: 22). [Diagram 3] FIG. 3 shows a representative example of the results of Example 3 (detection results when melting curve analysis was carried out using the probe shown in SEQ ID NO:8). [Figure 4] FIG. 4 shows a representative example of the results of Example 4 (detection results when melting curve analysis was carried out using the probe shown in SEQ ID NO: 13). [Diagram 5]Figure 5 shows the correspondence between a part of the ParC gene sequence (SEQ ID NO: 1) of Mycoplasma genitalium and the base sequences of each probe and primer used in the test example. The area enclosed in a square is the region of three bases (AGT or ATT in the example of Figure 5) corresponding to positions 247, 248, and 249 of the ParC gene sequence of Mycoplasma genitalium. The black circle indicates the binding position of the fluorescence quenching dye. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] The present invention will be described in further detail below with reference to embodiments of the present invention, but the present invention is not limited thereto. All non-patent and patent documents described in this specification are incorporated herein by reference and are incorporated in their entirety into the specification. In addition, in this specification, "~" means "more than or equal to, less than or equal to", for example, if the specification states "X~Y", it means "more than or equal to X, less than or equal to Y". In this specification, "and / or" means either one or both. In this specification, "comprising" includes the concepts of "consisting essentially of" and "consisting only of".
[0011] In addition, in this specification, a nucleic acid primer may be simply referred to as a primer, and a nucleic acid probe and a labeled probe may be simply referred to as a probe, and these are also collectively referred to as oligonucleotides.
[0012] In one embodiment, the present invention provides a method for detecting Mycoplasma genitalium by using a labeled probe having a specific base sequence. This method allows Mycoplasma genitalium to be detected simply, quickly, and with high sensitivity. In addition, the labeled probe targets a specific region having a mutation site associated with quinolone antibiotic resistance in the ParC gene sequence of Mycoplasma genitalium, and can detect both wild-type and quinolone antibiotic-resistant mutant types of Mycoplasma genitalium with a single type of labeled probe. In this specification, SEQ ID NO: 1 is a part of the ParC gene sequence of wild-type Mycoplasma genitalium. The probe of the present invention is preferably a labeled probe (also referred to as a "nucleic acid probe" in this specification) that targets a specific region of the base sequence shown in SEQ ID NO: 1 and has a specific base sequence.
[0013] [Methods for detecting Mycoplasma genitalium] In one embodiment, the method for detecting Mycoplasma genitalium that may be contained in a specimen sample is preferably a method using a nucleic acid probe described below. The method may be a method for determining whether Mycoplasma genitalium is present or absent in a specimen sample (particularly whether a quinolone antibiotic resistant mutant is present or absent). The method may also be a method for quantifying Mycoplasma genitalium (particularly a quinolone antibiotic resistant mutant) contained in a specimen sample. In a specific embodiment, by using one type of nucleic acid probe, Mycoplasma genitalium that may be contained in a specimen sample can be detected with high sensitivity in, for example, PCR-melting curve analysis (including RT-PCR-melting curve analysis), regardless of whether it is a wild type or a mutant type (particularly a quinolone antibiotic resistant mutant). In a further specific embodiment, for example, based on the difference in detection temperature in a melting curve analysis method or the like, Mycoplasma genitalium that may be contained in a specimen sample can be detected by distinguishing between wild type and mutant type (particularly quinolone antibiotic resistance mutant type), or the presence or absence of Mycoplasma genitalium mutations (particularly mutations associated with quinolone antibiotic resistance) (for example, the presence or absence of at least one mutation at positions 247, 248, 249, and optionally 259, particularly the presence or absence of a mutation at position 248) can be detected.
[0014] Antibiotics are substances that exhibit bacteriostatic or bactericidal effects against bacteria that cause infectious diseases, and are used to treat infectious diseases. There are various types of antibiotics, such as macrolides, tetracyclines, and quinolones, each of which has a different mechanism of action and targets differently. In addition, when a single base mutation or deletion occurs in the target of each antibiotic, these antibiotics may not be able to act and may not be effective. In this specification, the antibiotic is preferably a quinolone antibiotic such as a fluoroquinolone.
[0015] In a specific embodiment, a method for detecting Mycoplasma genitalium that may be contained in a specimen sample includes at least the following steps (1), (2), and (3): (1) providing a specimen sample that may contain Mycoplasma genitalium; (2) subjecting the specimen sample of step (1) to a nucleic acid amplification reaction using a part or all of the ParC gene sequence of Mycoplasma genitalium as a template; and (3) detecting one or more nucleic acid amplification products that may be generated in the nucleic acid amplification reaction of step (2) using one or more of the probes; In the method, it is preferable that step (2) is carried out by a PCR reaction, and step (3) is carried out by a melting curve analysis (PCR-melting curve analysis method). Steps (2) and (3) may be carried out in the same reaction solution.
[0016] [Process (1)] The specimen sample in step (1) is not particularly limited as long as it may contain Mycoplasma genitalium. Examples of specimen samples include biological samples such as animal and plant tissues, body fluids, excrement, and cells; environmental samples such as wipes of facility walls, floors, equipment, fixtures, toilets, etc., or cleaning fluids used to clean them. Suitable examples of specimen samples include, but are not limited to, blood, blood culture fluid, cervical scrapings, urethral scrapings, male urethral scrapings, urine, pus, cerebrospinal fluid, pleural effusion, pharyngeal swabs, nasal swabs, sputum, saliva, oral scrapings, tissue slices, skin, vomit, feces, isolated culture colonies, catheter washings, etc. collected from subjects (such as subjects suspected of infection with Mycoplasma genitalium). Considering that Mycoplasma genitalium is a major causative bacterium of sexually transmitted diseases, in a particular embodiment, the specimen sample is preferably, for example, tissue slice, skin, vomit, urine, isolated culture colony, cervical scraping, urethral scraping, male urethral scraping, urine, or throat swab, and more preferably urine. When a biological sample is used as the specimen sample to be measured, depending on the type of biological sample, etc., pretreatment such as dilution or suspension, centrifugation, enzyme treatment, filtration, heat treatment, acid treatment, alkali treatment, organic solvent treatment, crushing treatment, grinding treatment, or nucleic acid extraction may be performed, although this is not particularly limited.
[0017] The method of collecting and preparing the specimen is not particularly limited, and known methods can be used depending on the type and purpose of the specimen. In a particular preferred embodiment, the specimen does not need to be a sample from which DNA has been isolated or purified, and for example, a sample collected from a living body may be treated with a protease (e.g., proteinase K) and / or heat treated (e.g., at 60 to 100°C for 1 second to 10 minutes) to degrade and denaturate the sample, and DNase (DNA degrading enzyme) present in the sample may be degraded and removed in advance, and the sample may be used as is.
[0018] The method of nucleic acid extraction is not particularly limited, and a known method can be used depending on the type and purpose of the specimen. For example, a kit sold by each manufacturer may be used for nucleic acid extraction. Nucleic acid extraction may also be performed using an automatic extraction and purification device.
[0019] In a particular preferred embodiment, the specimen may be one in which the nucleic acid purification step, which is usually considered essential in conventional nucleic acid amplification reactions, has been omitted. In addition to the need for a dedicated reagent, nucleic acid purification has the problem that the work is complicated, time-consuming, and laborious. When a specimen without a nucleic acid purification step is used, the time from collection of the specimen to obtaining the genetic test result can be shortened, and for example, the time from collection of the specimen to obtaining the genetic test result can be within one day, preferably within half a day, more preferably within six hours, even more preferably within three hours, and particularly preferably within two hours (for example, within one hour). Thus, when the method of the present invention is performed using a specimen that has not undergone a nucleic acid purification step, the time required for nucleic acid purification can be omitted, and Mycoplasma genitalium can be detected easily and in a short time.
[0020] [Process (2)] In one embodiment, the nucleic acid amplification reaction in step (2) is preferably carried out by a nucleic acid amplification method (carrying out a nucleic acid amplification reaction using one or more primer sets). The nucleic acid amplification method is a technique for amplifying several copies of a target nucleic acid to a level at which it can be visualized, i.e., to hundreds of millions of copies or more, and is widely used not only in the field of life science research, but also in fields such as clinical diagnosis, food hygiene inspection, and environmental inspection. Examples of such nucleic acid amplification methods include PCR, LAMP, LCR, TMA, SDA, RT-PCR, RT-LAMP, NASBA, and TRC. These techniques have already been established in the technical field, and a method can be selected according to the purpose. The nucleic acid amplification method is preferably, but is not limited to, the PCR method (including the RT-PCR method).
[0021] (PCR reaction) PCR is a reaction catalyzed mainly by DNA polymerase. PCR usually includes three steps, namely (i) DNA denaturation by heat treatment (dissociation from double-stranded DNA to single-stranded DNA), (ii) annealing of a primer to a template single-stranded DNA, and (iii) extension of the primer using DNA polymerase, which are set as one cycle, and the cycle is repeated. Examples of DNA polymerase include Taq, Tth, Bst, KOD, Pfu, Pwo, Tbr, Tfi, Tfl, Tma, Tne, Vent, DEEPVENT, and mutants thereof. In the present invention, it is preferable to use a DNA polymerase belonging to family B from the viewpoints of simplicity, speed, high sensitivity, and resistance to amplification inhibition by a sample. In addition, when step (3) is performed by melting curve analysis, it is preferable to use a DNA polymerase belonging to family B that does not have 5'→3' exonuclease activity from the viewpoint of using a fluorescence quenching probe.
[0022] The conditions of the PCR reaction are not particularly limited as long as the reaction proceeds. For example, the first step (i) may be performed at 80 to 100°C for about 0 to 300 seconds (for example, about 0.5 to 300 seconds), the second or subsequent (repeated) step (i) may be performed at 80 to 100°C for about 0.5 to 300 seconds, step (ii) may be performed at 35 to 80°C for about 1 to 300 seconds, and step (iii) may be performed at 35 to 85°C for about 1 to 300 seconds. It is preferable that the cycle from step (i) to (iii) is repeated 30 to 70 times. The temperature and time of the repeated cycle may be changed every 1 to 3 cycles.
[0023] (DNA polymerase) The DNA polymerase that can be used in the nucleic acid amplification reaction, particularly the PCR reaction, in step (2) is preferably, but not limited to, a DNA polymerase belonging to family B. The DNA polymerase belonging to family B is not particularly limited, but is preferably a DNA polymerase derived from Archea, more preferably a DNA polymerase derived from bacteria of the genus Pyrococcus and Thermococcus. In addition, suitable DNA polymerases also include variants thereof that do not lose DNA polymerase activity derived from Archea belonging to family B. Examples of the variants include variants in which 1 to 3 amino acids are deleted, substituted, inserted and / or added in the wild-type amino acid sequence, or variants that show 80% or more, preferably 90% or more, more preferably 95% or more, and even more preferably 98% or more amino acid sequence identity with the wild-type amino acid sequence. Specifically, examples of the DNA polymerase variants include, but are not limited to, variants aimed at enhancing polymerase activity, deleting exonuclease activity, adjusting substrate specificity, and the like.
[0024] Examples of DNA polymerases derived from the genus Pyrococcus include, but are not limited to, DNA polymerases isolated from Pyrococcus furiosus, Pyrococcus sp. GB-D, Pyrococcus woesei, Pyrococcus abyssi, and Pyrococcus horikoshii, as well as mutants derived therefrom that have not lost their DNA polymerase activity.
[0025] Examples of DNA polymerases derived from the genus Thermococcus include, but are not limited to, DNA polymerases isolated from Thermococcus kodakaraensis, Thermococcus gorgonarius, Thermococcus litoralis, Thermococcus sp. JDF-3, Thermococcus sp. 9 degrees North-7 (Thermococcus sp. 9°N-7), and Thermococcus siculi, and mutants thereof that have not lost their DNA polymerase activity. Preferably, DNA polymerases derived from Thermococcus kodakaraensis and mutants thereof (e.g., KOD-derived DNA polymerase lacking 3'→5' exonuclease activity) can be particularly preferably used in the present invention from the viewpoint of excellent extensibility and thermal stability.
[0026] PCR enzymes using these DNA polymerases are commercially available, and examples of such enzymes include Pfu (Staragene), KOD (Toyobo), Pfx (Life Technologies), Vent (New England Biolabs), Deep Vent (New England Biolabs), Tgo (Roche), and Pwo (Roche), any of which can be used in the present invention.
[0027] (DNA polymerase derived from KOD) In the present specification, the term "KOD-derived DNA polymerase" refers to a DNA polymerase derived from Thermococcus kodakaraensis and its mutants (e.g., a KOD-derived DNA polymerase in which 3'→5' exonuclease activity has been deleted by substituting, deleting, inserting and / or adding one to three amino acids in the naturally occurring amino acid sequence). In one preferred embodiment, the nucleic acid amplification reaction in step (2) uses such a KOD-derived DNA polymerase. Compared to Taq DNA polymerase, which is a DNA polymerase belonging to family A, KOD DNA polymerase is superior in accuracy, amplification efficiency, extensibility and resistance to amplification inhibition by inhibitors derived from a specimen sample. In the present invention, the use of such a KOD DNA polymerase is more preferable in terms of simple, rapid and highly sensitive detection of Mycoplasma genitalium, as shown in the Examples described later.
[0028] (Primer set) The primer set that can be used in the nucleic acid amplification reaction of step (2) is not particularly limited as long as it can amplify a nucleic acid fragment derived from Mycoplasma genitalium with which the probe described below can form a complex. From the viewpoint of easily obtaining a more sensitive determination result, the primer set is preferably a primer set that can amplify a part or all of the ParC gene sequence of Mycoplasma genitalium (for example, a base sequence shown in SEQ ID NO: 1, or a base sequence that includes at least three base regions at positions corresponding to positions 247, 248, and 249 of the ParC gene sequence of Mycoplasma genitalium in the base sequence shown in SEQ ID NO: 1). In a further specific embodiment, it is preferable that the primer set is a primer set that can amplify a region containing a mutation (for example, A247C, G248T, and / or T249A mutation) in at least one position corresponding to positions 247, 248, and 249 of the ParC gene sequence. In yet another embodiment, the primer set may be capable of amplifying a region containing a mutation (e.g., A247C, G248T, T249A, G259A, and / or G259T mutation) in a base sequence having at least one of the positions corresponding to positions 247, 248, 249, and 259 of the ParC gene sequence.
[0029] For example, the primer set is preferably a primer set consisting of a combination of a first primer consisting of a base sequence of 19 to 32 consecutive bases in the base sequence of positions 1 to 71 of SEQ ID NO: 1 or a base sequence complementary to the said base sequence, and a second primer consisting of a base sequence of 19 to 32 consecutive bases in the base sequence of positions 99 to 142 of SEQ ID NO: 1 or a base sequence complementary to the said base sequence, wherein the second primer is complementary to a DNA extension product of the first primer.
[0030] More preferably, the primer set is composed of a primer consisting of a base sequence shown in any one of SEQ ID NOs: 18 and 19 or a base sequence complementary thereto, and a primer consisting of a base sequence shown in any one of SEQ ID NOs: 20 to 22 or a base sequence complementary thereto, wherein one primer is complementary to the DNA extension product of the other primer.
[0031] The primer set may also include primers having a base sequence in which 1 to 3 bases (preferably 1 or 2 bases, more preferably 1 base) have been substituted, deleted, inserted or added in the base sequence of each of the primers.
[0032] [Process (3)] The embodiment of step (3) is not particularly limited, and can be carried out by any method known in the art. The Mycoplasma genitalium to be detected can mutate like other infectious microorganisms. Here, if a mismatch occurs between the base sequence of the primer or probe and the base sequence of the target Mycoplasma genitalium mutant strain, the binding strength of the primer or probe to the target gene or the nucleic acid amplification product derived therefrom (target nucleic acid) can be reduced. In particular, when there are many mismatches between the target nucleic acid and the probe in the real-time PCR method, the probe cannot sufficiently bind to the target nucleic acid, so that the rise of the amplification curve may be delayed or may not rise at all, and such a situation may induce a false negative. In the case of the melting curve analysis method, since step (3) is performed after the completion of PCR, even if there is a mismatch in the primer or probe, detection is possible as long as the nucleic acid amplification product is finally obtained, so that the effect of mismatch can be suppressed more than in the real-time PCR method. Therefore, in step (3), it is particularly preferable to detect the nucleic acid amplification product by melting curve analysis. Furthermore, by detecting the nucleic acid amplification products using melting curve analysis, it may be possible to detect them in a shorter time (for example, 45 minutes or less, preferably 40 minutes or less, and more preferably 35 minutes or less from the start of the nucleic acid amplification reaction to the completion of melting curve analysis).
[0033] In one embodiment, step (3) comprises the following steps (3-1) and (3-2): (3-1) a step of hybridizing a nucleic acid amplification product that can be produced by the nucleic acid amplification reaction of the step (2) with a nucleic acid probe to form a complex; and (3-2) detecting the complex of step (3-1) In order to obtain a highly sensitive determination result in the detection of Mycoplasma genitalium, it is preferable to use a nucleic acid probe described below that can specifically react with a nucleic acid amplification product that can be generated in the nucleic acid amplification reaction in step (2) to form a complex. The hybridization in step (3-1) is preferably carried out under temperature conditions that allow sufficient hybridization of the nucleic acid amplification product with the nucleic acid probe, such as, but not limited to, a temperature at least 4°C lower than the Tm value of the nucleic acid probe, more preferably at least 6°C lower.
[0034] (Nucleic acid probe) The nucleic acid probe of the present invention may be a probe for detecting Mycoplasma genitalium, which has at least the following characteristics (A) and (B): (A) containing the following nucleotide sequence (A-1) or (A-2); (A-1) A base sequence of at least 15 consecutive bases in the base sequence of the region from base 72 to base 100 of the base sequence shown in SEQ ID NO: 1 or a base sequence complementary to the base sequence, the base sequence including at least a region of three bases corresponding to positions 247, 248, and 249 of the ParC gene sequence of Mycoplasma genitalium; or (A-2) a base sequence in which 1 to 3 bases are substituted, deleted, inserted or added in the base sequence of (A-1); and (B) Only either the 5' or 3' end is labeled. By using a nucleic acid probe having such characteristics, Mycoplasma genitalium can be detected with high sensitivity, for example, in melting curve analysis.
[0035] The nucleic acid probe of the present invention is not particularly limited as long as it has the base sequence of (A). However, in the case of a nucleic acid probe labeled with a fluorescent quenching dye that is quenched by interaction with guanine, as described below, it is preferable that at least one terminal base labeled with the dye is cytosine.
[0036] In one embodiment, the nucleic acid probe of the present invention can detect Mycoplasma genitalium (including mutant strains of Mycoplasma genitalium) containing in its genome a base sequence that shows 85% or more identity to the base sequence shown in SEQ ID NO:1, and can preferably be a nucleic acid probe that can detect Mycoplasma genitalium containing in its genome a base sequence that shows 90% or more identity to the base sequence shown in SEQ ID NO:1, more preferably 93% or more identity, even more preferably 95% or more identity, and even more preferably 98% or more identity.
[0037] In one embodiment, in the (A), the three bases at positions 247, 248, and 249 of the ParC gene sequence in the base sequence shown in SEQ ID NO: 1 are preferably selected from adenine, guanine, and thymine, and the sequence consisting of the three bases is preferably adenine-guanine-thymine (AGT) or adenine-thymine-thymine (ATT). When the base sequence of (A) is based on a base sequence complementary to the base sequence shown in SEQ ID NO: 1, the region of these three bases is also a complementary sequence, and is preferably adenine-cytosine-thymine (ACT) or adenine-adenine-thymine (AAT). Because the three bases at positions 247, 248, and 249 of the ParC gene sequence have such a sequence, it is possible to separate wild-type Mycoplasma genitalium from quinolone antibiotic-resistant mutant strains with greater specificity, and further to distinguish whether the mutant strain has a mutation at position 248 of the ParC gene sequence, which has been suggested to be particularly involved in resistance to quinolone antibiotics.
[0038] In a specific embodiment, the base sequence of (A) may be designed to include a region of one base at a position corresponding to the 259th position of the ParC gene sequence in the base sequence shown in SEQ ID NO: 1. When the base sequence of (A) is designed to include a region of one base at a position corresponding to the 259th position, the type of base is not particularly limited, but it is preferable that the base at the position corresponding to the 259th position of the ParC gene sequence in the base sequence shown in SEQ ID NO: 1 is designed to be a guanine base. Note that, when the base sequence of (A) is based on a base sequence complementary to the base sequence shown in SEQ ID NO: 1, it is preferable that the base at the position corresponding to the 259th position is also a cytosine base as a complementary base.
[0039] In a specific embodiment, the nucleic acid probe of the present invention may be a probe containing a base sequence (A-2) in which 1 to 3 bases are substituted, deleted, inserted or added in the base sequence shown in (A-1). The number of bases that can be substituted, deleted, inserted or added may preferably be 1 or 2. When a base is substituted, deleted, inserted or added in this way, the probe is said to contain a mismatched base, and a probe containing such a mismatched base can also be preferably used in the present invention. Such a mismatched base may be present at at least one of the positions corresponding to positions 247, 248, and 249 of the ParC gene sequence described above (or at least one of the positions corresponding to positions 247, 248, 249, and 259), or may be present in a region corresponding to a position other than these positions. In certain embodiments, in order to minimize the effect on binding of the probe to the target nucleic acid and on the detection of quinolone antibiotic resistant mutants, it is preferable that such mismatched bases are present in a region other than the positions corresponding to positions 247, 248, and 249 of the ParC gene sequence (or in a region other than the positions corresponding to positions 247, 248, 249, and 259).
[0040] In this specification, containing a mismatched base (or simply referred to as "mismatch") means containing a base that is not complementary to the base sequence of the target nucleic acid (in the case where the target nucleic acid becomes double-stranded after the nucleic acid amplification reaction, the base sequence of any one of the single-stranded nucleic acids resulting from the dissociation of the double strand). For example, when a cytosine base is present in the base sequence of the target nucleic acid, the base at the position corresponding to the cytosine base in the probe is other than a guanine base (for example, an adenine base, a cytosine base, a thymine base, and a universal base). For example, when detecting a region of the target nucleic acid that is prone to mutation, a mismatched base (for example, a universal base) can be selected at the position of the probe that corresponds to the base that is prone to mutation.
[0041] In one preferred embodiment, the nucleic acid probe of the present invention is a probe containing a base sequence of at least 15 consecutive bases in the base sequence of the 72nd to 100th region of the base sequence shown in SEQ ID NO: 1 or a base sequence complementary to the above base sequence, and which contains at least three bases corresponding to positions 247, 248, and 249 of the ParC gene sequence of Mycoplasma genitalium (positions corresponding to positions 82, 83, and 84 of the base sequence shown in SEQ ID NO: 1), or a base sequence in which one to three bases have been substituted, deleted, inserted, or added. In another preferred embodiment, the nucleic acid probe of the present invention is a probe having a base sequence of at least 15 consecutive bases in the base sequence of the 72nd to 100th regions of the base sequence shown in SEQ ID NO: 1 or a base sequence complementary to the base sequence, and including at least four bases corresponding to positions 247, 248, 249, and 259 of the ParC gene sequence of Mycoplasma genitalium (positions corresponding to positions 82, 83, 84, and 94 of the base sequence shown in SEQ ID NO: 1), or a base sequence in which one to three bases are substituted, deleted, inserted, or added in the base sequence. In these probes, the number of substituted, deleted, inserted, or added bases in the base sequence shown in SEQ ID NO: 1 or a base sequence complementary to the base sequence is preferably 0, 1, or 2, and more preferably 0 or 1. By reacting such a probe with a nucleic acid amplification product, Mycoplasma genitalium can be detected more effectively. In this specification, positions 247, 248, 249, and 259 in the ParC gene sequence of Mycoplasma genitalium refer to the positions determined by E. coli numbering, which is known in the art and is based on the numbering in the type strain of E. coli.
[0042] The length of the nucleic acid probe of the present invention (or the length of the base sequence of (A)) is not particularly limited as long as it is 15 bases or more, and is, for example, 16 bases or more, preferably 17 bases or more, more preferably 18 bases or more, and even more preferably 19 bases or more. The length of the probe is usually 30 bases or less, preferably 28 bases or less, more preferably 26 bases or less, and even more preferably 24 bases or less. The length of the probe can be, for example, 15 to 30 bases, more preferably 15 to 24 bases, and even more preferably 19 to 24 bases. By using a probe of such a length, Mycoplasma genitalium can be detected with higher sensitivity.
[0043] In a particular preferred embodiment, specific examples of the nucleic acid probe of the present invention include a probe containing a base sequence shown in any one of SEQ ID NOs: 7 to 17 or a base sequence complementary thereto, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in the base sequence, and preferably a probe containing a base sequence shown in any one of SEQ ID NOs: 7, 8, and 13 to 17 or a base sequence complementary thereto, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in the base sequence, and more preferably a probe containing a base sequence shown in any one of SEQ ID NOs: 8 and 13 or a base sequence complementary thereto, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in the base sequence. By using a probe having such a specific base sequence, Mycoplasma genitalium can be detected with even higher sensitivity.
[0044] In a further specific preferred embodiment, the nucleic acid probe of the present invention is preferably designed so that the difference between the detection temperature of the wild type and the detection temperature of the mutant type (particularly the mutant type resistant to quinolone antibiotics) in melting curve analysis is 4° C. or more, preferably 6° C. or more, more preferably 7° C. or more, and even more preferably 8° C. or more. The difference in detection temperature is, for example, 20° C. or less, preferably 15° C. or less.
[0045] The nucleic acid probe is characterized in that only one of the 5'-end or 3'-end is labeled. In one embodiment, the nucleic acid probe of the present invention is preferably labeled to generate quenching or fluorescence when bound to a nucleic acid containing a base sequence that shows 85% or more, preferably 90% or more, more preferably 93% or more, even more preferably 95% or more, and even more preferably 98% or more identity with a base sequence complementary to the base sequence of the nucleic acid probe, and more preferably labeled to generate quenching. The labeling substance is not particularly limited, but is more preferably a fluorescent dye.
[0046] The fluorescent dye may be either a fluorescent substance that generates fluorescence or a fluorescent substance that quenches fluorescence by hybridizing with a target nucleic acid amplification product to form a complex, but is preferably a fluorescent substance that quenches fluorescence when hybridized with a target nucleic acid amplification product, and is particularly preferably a fluorescence quenching dye that is quenched by interaction with guanine when hybridized with a target nucleic acid amplification product (for example, a fluorescence quenching dye that is quenched by interaction with guanine). Specific examples of the fluorescent quenching dye include, but are not limited to, at least one fluorescent quenching dye selected from the group consisting of fluorescein and its derivatives (e.g., fluorescein isothiocyanate (FITC)), rhodamine and its derivatives (e.g., 5-carboxyrhodamine 6G (GR6G), tetramethylrhodamine (TAMRA), carboxyrhodamine, x-rhodamine, sulforhodamine 101 acid chloride), and BODIPY and its derivatives (e.g., BODIPY-FL, BODIPY-FL / C3, BODIPY-FL / C6, BODIPY-5-FAM, BODIPY-TMR, BODIPY-TR, BODIPY-R6G, BODIPY-564, BODIPY-581, BODIPY-591, BODIPY-630, BODIPY-650, BODIPY-665).
[0047] More specifically, examples of the fluorescence quenching dye that is quenched by interaction with guanine include at least one fluorescence quenching dye selected from the group consisting of 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid (BODIPY-FL), carboxyrhodamine 6G (CR6G), TAMRA, rhodamine 6G, tetrabromosulfonefluorescein (TBSF), and 2-oxo-6,8-difluoro-7-dihydroxy-2H-1-benzopyran-3-carboxylic acid (Pacific Blue), and these fluorescence quenching dyes can be suitably used in the present invention.
[0048] In a particular preferred embodiment, a probe having a terminal base labeled with a fluorescence quenching dye that is cytosine is more preferred. When such a probe hybridizes to a target nucleic acid amplification product, it can form a base pair with a guanine base in the nucleic acid amplification product and interact with it to quench the light, making it very easy to measure the change in the fluorescence intensity of the reaction solution.
[0049] In addition, when the probe is hybridized, even if the cytosine base of the probe and the guanine base in the nucleic acid amplification product do not form a base pair, the fluorescence can be quenched as long as the distance between these bases is close. For example, details are described in Japanese Patent No. 5354216, and the present invention can also refer to this technology. That is, when the probe is hybridized, the fluorescence can be quenched if the guanine base in the nucleic acid amplification product is present within a range of, for example, 1 to 3 bases relative to the cytosine base of the probe (a base that forms a base pair with the cytosine base is considered to be 1).
[0050] Therefore, even if at least one terminal base labeled with a fluorescence quenching dye is not cytosine, the change in the fluorescence intensity of the reaction solution can be measured. For example, details are described in Japanese Patent No. 5354216, and the present invention can also refer to this technology. For example, when the probe is hybridized, quenching can be achieved if a guanine base in the nucleic acid amplification product is present within a range of, for example, 1 to 3 bases relative to the terminal base labeled with the fluorescence quenching dye (the base that forms a base pair with the terminal base is counted as 1).
[0051] In a particular preferred embodiment, the nucleic acid probe of the present invention is used in step (3). In this way, the nucleic acid probe of the present invention can be used to detect wild-type and / or mutant types (particularly quinolone antibiotic-resistant mutant types) of Mycoplasma genitalium. The method of the present invention may use one type of probe of the present invention or a combination of two or more types. In a particular preferred embodiment, the method of the present invention can detect both wild-type and mutant types (particularly quinolone antibiotic-resistant mutant types) of Mycoplasma genitalium by using only one type of labeled probe. In a further preferred embodiment, the detected Mycoplasma genitalium can be detected by distinguishing whether it is a wild-type that is sensitive to antibiotics (particularly quinolone antibiotics) or a mutant type that is resistant to antibiotics (particularly quinolone antibiotics).
[0052] In one embodiment, the step (3) may include at least one of the following steps (3-a), (3-b), and (3-c): (3-a) Simultaneously with step (2), a step of hybridizing the nucleic acid probe of the present invention to the nucleic acid amplification product in the reaction solution of the nucleic acid amplification reaction and measuring the fluorescence intensity of the reaction solution, thereby monitoring the progress of the reaction (nucleic acid amplification reaction) of step (2) in real time. (3-b) After completion of step (2), a step of hybridizing the nucleic acid probe of the present invention to the nucleic acid amplification product in the reaction solution of the nucleic acid amplification reaction and measuring the fluorescence intensity of the reaction solution, thereby monitoring the progress of the reaction of step (2) (nucleic acid amplification reaction) at an endpoint. (3-c) after completion of the step (2), hybridizing the nucleic acid probe of the present invention to the nucleic acid amplification product in the reaction solution of the nucleic acid amplification reaction and measuring the temperature dependence of the fluorescence intensity of the reaction solution. By the step (3-a), (3-b), or (3-c), the formation of a complex formed between a nucleic acid amplification product and a nucleic acid probe can be detected simply, quickly, and with high sensitivity. The steps (3-a), (3-b), and (3-c) may be performed in combination, for example, both steps (3-a) and (3-b), or both steps (3-a) and (3-c) can be performed. In one embodiment, from the viewpoint of more rapid detection of a nucleic acid amplification product, the step (3-b) or (3-c) is preferred. In particular, the step (3-c), i.e., the melting curve analysis method, is preferred.
[0053] (Step (3-a)) Step (3-a) is a method for monitoring the progress of a nucleic acid amplification reaction in real time (so-called real-time PCR method), and quantitative analysis is possible by comparing with a control substance of known concentration.
[0054] (Step (3-b)) In step (3-b), the progress of the nucleic acid amplification reaction is monitored at the end point, thereby enabling rapid detection of the target nucleic acid contained in the specimen. Furthermore, the approximate amount of the target nucleic acid can be estimated by comparing the fluorescence intensity at the end point. For example, the progress of the nucleic acid amplification reaction is monitored at an end point by measuring the fluorescence intensity of a reaction solution containing a nucleic acid probe labeled with a fluorescent quenching dye. After the nucleic acid amplification reaction is completed, the fluorescence intensity of the reaction solution is measured and the fluorescence intensity of the reaction solution after the reaction is compared with the fluorescence intensity of the reaction solution before the reaction, thereby confirming the presence or absence of amplification of the target nucleic acid. Alternatively, the presence or absence of the target nucleic acid in the specimen sample can also be confirmed by comparing the fluorescence intensity of the reaction solution after the reaction with the fluorescence intensity of a control reaction solution. The control reaction solution is a reaction solution to which a sample known to be negative or positive is added instead of the specimen sample to be measured. The progress of the nucleic acid amplification reaction generally needs to be monitored in real time, but for the purpose of more rapid and convenient detection, it is preferable to measure it at an end point.
[0055] (Step (3-c)) In step (3-c), measuring the temperature dependency of the fluorescence intensity may specifically mean measuring the fluorescence intensity at each temperature while changing the temperature of the reaction solution from low to high. The melting temperature (Tm value) specific to the nucleic acid probe used can be obtained by first differentiating the obtained fluorescence intensity with respect to temperature. The fluorescence intensity may also be converted into a fluorescence quenching rate or the like according to the purpose. The detection and analysis of target nucleic acids using the Tm value is called melting curve analysis. In general, the Tm value refers to the temperature at which the proportion of an oligonucleotide that forms a double strand with its complementary strand is equal to the proportion that does not form a double strand and is single-stranded. Since the Tm value is a value specific to a base sequence, melting curve analysis can be used as a method for analyzing base sequence polymorphisms of target nucleic acids. Base sequence polymorphisms referred to here include single nucleotide polymorphisms, base substitutions, base deletions, base insertions, etc.
[0056] As an example, melting curve analysis is also applied to SNP analysis. When there is a mutation in the base sequence of the target nucleic acid relative to the probe, the bases mismatch when the probe hybridizes, and the Tm value is generally low. Therefore, single nucleotide polymorphism analysis (SNP analysis) can also be performed by comparing the magnitude of the Tm value.
[0057] In the present invention, it is preferable to perform melting curve analysis in step (3-c) and monitor in real time the intensity of the fluorescence or quenching signal generated as the probe dissociates from the target sequence in response to temperature change. When the first derivative value obtained by differentiating the change in emission or quenching signal intensity with an increase in temperature by the temperature change value is plotted, the melting temperature can be displayed as a peak in the obtained melting curve (temperature-first derivative curve). In this specification, for example, the melting temperature displayed as a peak when melting curve analysis is performed using a specific probe is referred to as the detection temperature of the probe.
[0058] When a mutation occurs in the target nucleic acid, a double-stranded gene with a mismatch is formed by performing PCR. In this way, the double-stranded gene with a mismatch easily denatures (dissociates) the double-stranded structure, and the detection temperature may be lower than that of a wild-type gene without a mismatch during melting curve analysis. Therefore, when a mutation occurs in the target nucleic acid that causes a mismatch with the probe sequence, a change in the detection temperature (lowering) can be detected.
[0059] Therefore, when using a probe in which the three (and four, if necessary) bases corresponding to positions 247, 248, and 249 (and 259, if necessary) of the ParC gene sequence of Mycoplasma genitalium are all the same as those of the wild type, when the Mycoplasma genitalium contained in the sample is a mutant strain (especially a mutant strain resistant to quinolone antibiotics), dissociation of one or more bases occurs between the probe and the target sequence, denaturation (dissociation) of the double-stranded structure occurs easily, and the detection temperature in the melting curve analysis can be lowered compared to when detecting the wild type. On the other hand, when a probe is used in which the three (and four, if necessary) bases corresponding to positions 247, 248, and 249 (and 259, if necessary) of the ParC gene sequence of Mycoplasma genitalium are all the same as those of the mutant type, when Mycoplasma genitalium contained in the sample is wild type, dissociation of one or more bases occurs between the probe and the target sequence, so that denaturation (dissociation) of the double-stranded structure easily occurs, and the detection temperature in the melting curve analysis can be lowered compared to the case of detecting the mutant type. The difference in the detection temperature is, for example, 4°C or more, preferably 6°C or more, more preferably 7°C or more, and even more preferably 8°C or more. The difference in the detection temperature is, for example, 20°C or less, preferably 15°C or less.
[0060] [Reagents for detecting Mycoplasma genitalium] In another embodiment, the present invention provides a reagent for detecting Mycoplasma genitalium. The reagent preferably contains at least components necessary for nucleic acid amplification reaction and detection in addition to the nucleic acid probe of the present invention described above. The necessary components can be those known in the art. For example, the reagent of the present invention preferably contains at least a primer set for nucleic acid amplification such as PCR, DNA polymerase, deoxyribonucleoside triphosphates (dNTPs), and inorganic salts such as magnesium salts. The primer set for nucleic acid amplification and the nucleic acid probe for detection can contain multiple sets in order to amplify multiple regions of Mycoplasma genitalium. The concentration of each component can be appropriately adjusted, but for example, the concentration of the nucleic acid probe is preferably 0.01 to 1 μM, more preferably 0.02 to 0.5 μM. When used as a nucleic acid probe set, each nucleic acid probe contained in the probe set is preferably within the above concentration range. The concentration of each primer in the primer set is preferably 0.01 to 10 μM. The concentration of DNA polymerase is preferably 0.01 to 1 U / μL, more preferably 0.02 to 0.5 U / μL. The concentration of deoxyribonucleoside triphosphates (dNTPs) is preferably 0.02 to 1 mM, more preferably 0.1 to 0.5 mM. The concentration of inorganic salts such as magnesium salts is preferably 0.1 to 10 mM, more preferably 1 to 5 mM.
[0061] Furthermore, for the purpose of suppressing non-specific amplification and promoting the reaction, the reagent of the present invention may contain additives known in the art. Examples of additives for suppressing non-specific amplification include known anti-DNA polymerase antibodies, phosphoric acid, etc. Examples of additives for promoting the reaction include bovine serum albumin (BSA), protease inhibitors, single-stranded binding protein (SSB), T4 gene 32 protein, tRNA, sulfur- or acetic acid-containing compounds, dimethyl sulfoxide (DMSO), glycerol, ethylene glycol, propylene glycol, trimethylene glycol, formamide, acetamide, betaine, ectoine, trehalose, dextran, polyvinylpyrrolidone (PVP), gelatin, tetramethylammonium chloride (TMAC), tetramethylammonium hydroxide (TMAH), tetramethylammonium acetate (TMAA), polyethylene glycol, carnitine, Triton, Tween 20, and Nonidet (registered trademark) P40. In order to facilitate the determination of false negatives, the reagent of the present invention preferably contains an internal control known in the art. In the present invention, these additives may be used alone or in combination of two or more.
[0062] [Reagent kit for detecting Mycoplasma genitalium] In another embodiment, the present invention provides a reagent kit for detecting Mycoplasma genitalium. The kit of the present invention is not particularly limited as long as it contains the nucleic acid probe of the present invention or the reagent of the present invention described above and is configured to detect (including differentiation) Mycoplasma genitalium. For example, the kit of the present invention can optionally contain a reagent capable of detecting or quantifying the presence of a target substance, and / or an instruction manual for use that explains how to use the kit. For example, the kit of the present invention can be provided in a form in which the nucleic acid probe, components necessary for a nucleic acid amplification reaction, and components necessary for detecting a nucleic acid amplification product are sealed in the same container or in separate containers, and packaged in, for example, a single package, and includes information on how to use the kit. The kit of the present invention can also contain a positive control solution and / or a negative control solution. EXAMPLES
[0063] The present invention will be specifically described below by showing examples, but the present invention is not limited to these examples.
[0064] Example 1: Low copy number detection evaluation of wild-type Mycoplasma genitalium (1-1) Method In order to evaluate a probe that can specifically detect Mycoplasma genitalium even when only a low copy of wild-type Mycoplasma genitalium is present, 25 copies of genomic DNA consisting of the base sequence of the wild-type Mycoplasma genitalium gene were added as a template per reaction, and the presence or absence of non-specific amplification and the detection of wild-type Mycoplasma genitalium target nucleic acid were evaluated with various probes. The probe used was a nucleic acid consisting of the base sequences shown in SEQ ID NOs: 7 to 17, synthesized according to a conventional method (only one end was labeled with CR6G, see Figure 5). In addition, a primer set consisting of a primer consisting of the base sequence shown in SEQ ID NO: 19 and a primer consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 22 was used for the nucleic acid amplification reaction.
[0065] (1-2) Reaction solution A reaction solution containing the components shown below was prepared using GeneCube (registered trademark) Test Basic (manufactured by Toyobo Co., Ltd.). 3.0 μM primer consisting of the base sequence shown in SEQ ID NO:19 0.5 μM of a primer consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 22 0.5 μM of a probe consisting of a base sequence shown in any one of SEQ ID NOs: 7 to 17 (1-3) Reaction Using GENECUBE (registered trademark), the reaction solution was reacted in the following temperature cycles, and the fluorescence intensity in each cycle was measured. 94℃ 30 seconds 97℃ 1 sec -58℃ 5 sec -68℃ 5 sec (60 cycles) (1-4) Results FIG. 1 is a detection graph obtained when detecting wild-type Mycoplasma genitalium by nucleic acid amplification and melting curve analysis using the probe shown in SEQ ID NO: 8 as a representative example. The measurement results using the probe used in this example are summarized in Table 1. In Table 1, "+" means detectable. The fluorescence change rate (representing the quenching rate in this example) was calculated by the formula (fluorescence intensity before amplification-fluorescence intensity after amplification) / (fluorescence intensity before amplification). In this example, a test was performed using a template DNA with a very low copy number of 25 copies. As shown in the results in Table 1 below, it was revealed that by using the probe of the present invention, it is possible to detect wild-type Mycoplasma genitalium even when only a low copy number is present.
[0066] [Table 1]
[0067] [Example 2: Evaluation by combination with primers] (2-1) Method In order to evaluate a probe capable of specifically detecting the wild-type Mycoplasma genitalium, 25 copies of genomic DNA consisting of the base sequence of the wild-type gene of Mycoplasma genitalium were added as a template per reaction, and the presence or absence of non-specific amplification and the detection of the target nucleic acid of wild-type Mycoplasma genitalium were evaluated using a total of six combinations of primers consisting of either one of SEQ ID NOs: 18 and 19 and either one of SEQ ID NOs: 20 to 22. The primers used were nucleic acids consisting of the base sequences shown in SEQ ID NOs: 18 to 22, which were synthesized according to a conventional method. A probe consisting of the base sequence shown in SEQ ID NO: 8 was also used.
[0068] (2-2) Reaction solution A reaction solution containing the components shown below was prepared using GeneCube (registered trademark) Test Basic (manufactured by Toyobo Co., Ltd.). 3.0 μM of a primer consisting of a base sequence shown in either SEQ ID NO: 18 or 19 0.5 μM of a primer consisting of a base sequence complementary to any of the base sequences shown in SEQ ID NOs: 20 to 22 0.5 μM Probe consisting of the base sequence shown in SEQ ID NO:8 (2-3) Reaction Using GENECUBE (registered trademark), the reaction solution was reacted in the following temperature cycles, and the fluorescence intensity in each cycle was measured. 94℃ 30 seconds 97℃ 1 sec -58℃ 5 sec -68℃ 5 sec (60 cycles) (2-4) Results Fig. 2 shows a detection graph obtained when wild-type Mycoplasma genitalium was detected by nucleic acid amplification and melting curve analysis using the primer set shown in SEQ ID NO: 18 and SEQ ID NO: 22 as a representative example. The measurement results using the probes used in this example are summarized in Table 2. In Table 2, "+" means detectable. The rate of change in fluorescence (representing the quenching rate in this example) was calculated by the formula (fluorescence intensity before amplification - fluorescence intensity after amplification) / (fluorescence intensity before amplification). As shown in the results in Table 2, it was revealed that all primer set combinations were capable of detecting the wild-type Mycoplasma genitalium at a very low copy number of 25 copies, as in Example 1.
[0069] [Table 2]
[0070] [Example 3: Detection and evaluation of antibiotic-resistant mutants of Mycoplasma genitalium] (3-1) Method In order to evaluate a probe capable of distinguishing and detecting mutant Mycoplasma genitalium from wild type at the detection temperature, 100 copies of genomic DNA consisting of the base sequence of the wild type gene of Mycoplasma genitalium and a synthetic gene sequence consisting of the base sequence of the mutant ParC gene of Mycoplasma genitalium (a single base mutation exists at the position corresponding to the 247th, 248th, 249th, or 259th position) were added as templates per reaction, and the detection temperatures of wild type and mutant Mycoplasma genitalium were evaluated with a total of three types of probes. The probes used were nucleic acids consisting of the base sequences shown in SEQ ID NOs: 7 to 9, synthesized according to a conventional method (only one end was labeled with BODIPY-FL, see FIG. 5). In addition, a primer set consisting of a primer consisting of the base sequence shown in SEQ ID NO: 19 and a primer consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 22 was used for the nucleic acid amplification reaction.
[0071] (3-2) Reaction solution A reaction solution containing the components shown below was prepared using GeneCube (registered trademark) Test Basic (manufactured by Toyobo Co., Ltd.). 3.0 μM primer consisting of the base sequence shown in SEQ ID NO:19 0.5 μM of a primer consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 22 0.5 μM of a probe consisting of a base sequence shown in any one of SEQ ID NOs: 7 to 9 (3-3) Reaction Using GENECUBE (registered trademark), the reaction solution was reacted in the following temperature cycles, and the fluorescence intensity in each cycle was measured. 94℃ 30 seconds 97℃ 1 sec -58℃ 5 sec -68℃ 5 sec (60 cycles) (3-4) Results FIG. 3 is a detection graph obtained when detecting mutant forms of Mycoplasma genitalium (representing wild type and 247-position mutant forms) by nucleic acid amplification and melting curve analysis using the probe shown in SEQ ID NO: 8 as a representative example. The measurement results using the probe used in this example are summarized in Table 3. In Table 3, "+" means detectable. The rate of change in fluorescence (representing the quenching rate in this example) was calculated by the formula (fluorescence intensity before amplification - fluorescence intensity after amplification) / (fluorescence intensity before amplification). As shown in the results in Table 3, it was demonstrated that mutant forms of Mycoplasma genitalium can be detected by using the probe of the present invention. In addition, from the difference in the fluorescence change rate and detection temperature when detecting the wild type and mutant forms, it was confirmed that, particularly when using a probe consisting of the base sequence shown in either of SEQ ID NOs: 7 and 8, the wild type and mutant forms of Mycoplasma genitalium can be clearly distinguished from each other with a detection temperature difference of about 4°C or more, regardless of whether the type has a mutation at position 247, 248, 249, or 259.
[0072] [Table 3]
[0073] [Example 4: Detection and evaluation of the presence or absence of a mutation at position 248 of ParC in Mycoplasma genitalium] (4-1) Method In order to evaluate the probes capable of distinguishing and detecting the presence or absence of a mutation at position 248 of ParC of Mycoplasma genitalium at the detection temperature, 100 copies of genomic DNA consisting of the base sequence of the wild-type gene of Mycoplasma genitalium and a synthetic gene sequence consisting of a base sequence containing or not containing a single base mutation at position 248 of the ParC gene of Mycoplasma genitalium were added as templates per reaction, and the detection temperatures of wild-type and antibiotic-resistant mutant forms of Mycoplasma genitalium were evaluated using a total of 10 types of probes. The probes used were nucleic acids consisting of the base sequences shown in SEQ ID NOs: 7 to 17, synthesized according to a conventional method (only one end was labeled with BODIPY-FL, see Figure 5). In addition, a primer set consisting of a primer consisting of the base sequence shown in SEQ ID NO: 19 and a primer consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 22 was used for the nucleic acid amplification reaction.
[0074] (4-2) Reaction solution A reaction solution containing the components shown below was prepared using GeneCube (registered trademark) Test Basic (manufactured by Toyobo Co., Ltd.). 3.0 μM primer consisting of the base sequence shown in SEQ ID NO:19 0.5 μM of a primer consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 22 0.5 μM of a probe consisting of a base sequence shown in any one of SEQ ID NOs: 7 to 17 (4-3) Reaction Using GENECUBE (registered trademark), the reaction solution was reacted in the following temperature cycles, and the fluorescence intensity in each cycle was measured. 94℃ 30 seconds 97℃ 1 sec -58℃ 5 sec -68℃ 5 sec (60 cycles) (4-4) Results Fig. 4 is a detection graph obtained when detecting the presence or absence of a mutation at ParC position 248 of Mycoplasma genitalium by nucleic acid amplification and melting curve analysis using the probe shown in SEQ ID NO: 13 as a representative example. The measurement results using the probe used in this example are summarized in Table 4. In Table 4, "+" means detectable. The rate of change in fluorescence (representing the quenching rate in this example) was calculated by the formula (fluorescence intensity before amplification - fluorescence intensity after amplification) / (fluorescence intensity before amplification). As shown in the results of Table 4, it was shown that the presence or absence of a mutation at position 248 of ParC of Mycoplasma genitalium can be detected by using the probe of the present invention. In particular, it was confirmed that the presence or absence of a mutation at position 248 of the ParC gene sequence of Mycoplasma genitalium can be more clearly identified by the difference in the fluorescence change rate and detection temperature when detecting the wild type and mutant type, particularly when using a probe consisting of a base sequence shown in any of SEQ ID NOs: 7, 8, and 13 to 17. It has been suggested in recent years that the mutation at position 248 of the ParC gene sequence is particularly strongly involved in quinolone antibiotic resistance. Therefore, it is very significant that the use of probes having these specific base sequences can more clearly distinguish the wild type of Mycoplasma genitalium from the mutant type to which quinolone antibiotics are resistant.
[0075] [Table 4]
[0076] FIG. 5 shows the correspondence between a part of the ParC gene sequence (SEQ ID NO: 1) of Mycoplasma genitalium and the sequence of each probe used in this example. The boxed parts are three bases corresponding to positions 247, 248, and 249 of the ParC gene of Mycoplasma genitalium that may be related to antibiotic resistance, and the black circles indicate the binding positions of the fluorescent quenching dye. Considering the results of Tables 4 and 5 together, it was shown that by using a probe having a specific base sequence of the present invention, it is possible to distinguish between a wild type and a mutant type of Mycoplasma genitalium (a mutant strain having a mutation at at least one position of positions 247, 248, and 249 (and position 259 as necessary) of the ParC gene sequence of Mycoplasma genitalium with a detection temperature difference of, for example, 4°C or more, and that by using a probe having a base sequence shown in any of SEQ ID NOs: 7, 8, and 13 to 17, it is possible to clearly distinguish with an even larger detection temperature difference. [Industrial Applicability]
[0077] By using the nucleic acid probe of the present invention, Mycoplasma genitalium that may be contained in a sample can be detected simply, quickly, and with high sensitivity, for example, in a melting curve analysis method. The present invention makes it possible to detect Mycoplasma genitalium with high reliability, which can greatly contribute to clinical diagnosis, etc. In addition, the present invention can also determine whether Mycoplasma genitalium contained in a specimen sample is resistant to quinolone antibiotics, which allows treatment with an appropriate antibacterial drug for each patient in clinical diagnosis, thereby greatly contributing to preventing the spread of sexually transmitted diseases.
Claims
1. A probe for detecting Mycoplasma genitalium, having the following characteristics (A) and (B): (A) containing the following base sequence (A-1) or (A-2); (A-1) A base sequence of at least 15 consecutive bases in the base sequence of the 72nd to 100th regions of the base sequence shown in SEQ ID NO: 1 or a base sequence complementary to the above base sequence, which includes at least a region of three bases corresponding to positions 247, 248, and 249 of the ParC gene sequence of Mycoplasma genitalium; or (A-2) A base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in the base sequence of (A-1); and (B) Only either the 5' or 3' end is labeled.
2. The probe described in claim 1, wherein in (A), the three bases at positions corresponding to positions 247, 248, and 249 of the ParC gene sequence in the base sequence shown in SEQ ID NO: 1 are each independently selected from an adenine base, a guanine base, and a thymine base.
3. The probe according to claim 1, wherein in (A), a sequence consisting of three bases at positions corresponding to 247th, 248th, and 249th of the ParC gene sequence in the base sequence shown in SEQ ID NO: 1 is AGT or ATT.
4. The probe according to claim 1, wherein the base sequence of (A) comprises a base sequence shown in any one of SEQ ID NOs: 7 to 17 or a base sequence complementary thereto.
5. The probe according to claim 1, wherein the length of the base sequence of (A) is 15 to 30 bases.
6. The probe according to claim 1 , wherein the label (B) is a fluorescent dye label.
7. The probe according to claim 1, wherein the label (B) is a label with a fluorescent quenching dye that is quenched when bound to a nucleic acid containing a base sequence that is 90% or more identical to a base sequence complementary to the base sequence of the probe.
8. The probe according to claim 1 , wherein the label (B) is a label with a fluorescent quenching dye that is quenched by interaction with guanine.
9. The probe according to claim 1, wherein the label (B) is a label with at least one fluorescence quenching dye selected from the group consisting of fluorescein and its derivatives, rhodamine and its derivatives, and BODIPY and its derivatives.
10. The probe according to claim 1, wherein the label of (B) is a label with at least one fluorescence quenching dye selected from the group consisting of 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid (BODIPY-FL), carboxyrhodamine 6G, TAMRA, rhodamine 6G, tetrabromosulfonefluorescein (TBSF), and 2-oxo-6,8-difluoro-7-dihydroxy-2H-1-benzopyran-3-carboxylic acid (Pacific Blue).
11. The probe according to claim 1 , wherein in (B), the labeled terminal base is cytosine.
12. A method for detecting Mycoplasma genitalium which may be contained in a specimen sample, using the probe according to any one of claims 1 to 11.
13. The following steps (1), (2), and (3): (1) providing a specimen sample that may contain Mycoplasma genitalium; (2) subjecting the specimen sample of step (1) to a nucleic acid amplification reaction using a part or all of the ParC gene sequence of Mycoplasma genitalium as a template; and (3) detecting one or more nucleic acid amplification products that may be generated in the nucleic acid amplification reaction of the step (2) using one or more of the probes; The method of claim 12, comprising:
14. The method according to claim 13, wherein the step (2) is carried out by a PCR reaction, and the nucleic acid amplification enzyme used in the PCR reaction is a DNA polymerase belonging to family B.
15. The method according to claim 14, wherein the DNA polymerase belonging to family B is a DNA polymerase derived from KOD or a mutant thereof.
16. The method according to claim 13, wherein the primer set used in the nucleic acid amplification reaction in the step (2) is a combination of a first primer consisting of a base sequence of 19 to 32 consecutive bases in the base sequence of positions 1 to 71 of SEQ ID NO: 1 or a base sequence complementary to said base sequence, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said base sequence, and a second primer consisting of a base sequence of 19 to 32 consecutive bases in the base sequence of positions 99 to 142 of SEQ ID NO: 1 or a base sequence complementary to said base sequence, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said base sequence, wherein the second primer is complementary to a DNA extension product of the first primer.
17. The method according to claim 16, wherein the first primer comprises a nucleotide sequence represented by any one of SEQ ID NOs: 18 and 19, or a complementary nucleotide sequence thereto, or a nucleotide sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said nucleotide sequence, and the second primer comprises a nucleotide sequence represented by any one of SEQ ID NOs: 20 to 22, or a complementary nucleotide sequence thereto, or a nucleotide sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said nucleotide sequence.
18. The method of claim 12, wherein both wild-type and quinolone antibiotic-resistant mutant forms of Mycoplasma genitalium are detected.
19. The method according to claim 12, which detects Mycoplasma genitalium by distinguishing between a wild type and a mutant type resistant to a quinolone antibiotic.
20. The method according to claim 12, which discriminates and detects the presence or absence of at least one mutation at positions 247, 248, and 249 of the ParC gene sequence of Mycoplasma genitalium.
21. The method according to claim 12, which discriminates and detects the presence or absence of a mutation at position 248 of the ParC gene sequence of Mycoplasma genitalium.
22. 14. The method of claim 13, wherein the detecting step in step (3) is carried out by melting curve analysis.
23. 23. The method according to claim 22, wherein in the melting curve analysis, the detection temperature of a resistant mutant to a quinolone antibiotic is detected at a lower or higher temperature than the detection temperature of a wild type.
24. 23. The method of claim 22, wherein in the melting curve analysis, the difference between the detection temperature of a quinolone antibiotic-resistant mutant and the detection temperature of a wild type is 4°C or more.
25. 23. The method of claim 22, wherein in the melting curve analysis, the difference between the detection temperature of a quinolone antibiotic-resistant mutant and the detection temperature of a wild type is 8°C or more.
26. A reagent kit for detecting Mycoplasma genitalium, comprising the probe according to any one of claims 1 to 11.
27. The reagent kit according to claim 26, further comprising a primer set consisting of a combination of a first primer consisting of a base sequence of 1 to 71 of the base sequence shown in SEQ ID NO: 1 or a base sequence of 19 to 32 consecutive bases in a base sequence complementary to said base sequence, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said base sequence, and a second primer consisting of a base sequence of 99 to 142 of the base sequence shown in SEQ ID NO: 1 or a base sequence of 19 to 32 consecutive bases in a base sequence complementary to said base sequence, or a base sequence in which 1 to 3 bases have been substituted, deleted, inserted or added in said base sequence, wherein the second primer is complementary to a DNA extension product of the first primer.
